Johnson & Johnson vs Monster Beverage Corp — how do they compare? Johnson & Johnson trades at $260.77 (market cap $626.09B), while Monster Beverage Corp trades at $46.06 (market cap $89.20B). The key difference: Johnson & Johnson is far larger — about 7× Monster Beverage Corp's market cap, and Johnson & Johnson pays a 2.06% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| JNJ | MNST | |
|---|---|---|
Market Cap | $626.09B | $89.20B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $49.97 |
52-Week Low | $172.78 | $30.86 |
Enterprise Value | $654.37B | $87.49B |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Monster Beverage (MNST) trades at $45.895, up 0.45% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, achieving a 23.08% net margin. Recent Q2 2026 results beat expectations with $0.60 EPS versus $0.59 expected, driven by international growth. A 2-for-1 stock split occurred on August 11, 2026, while analyst consensus remains positive with 51% buy ratings and a $51.14 price target.
MNST's outlook is supported by robust earnings growth and global expansion, but elevated valuation ratios (P/E 42.16, P/S 9.75) pose risks. Competitive pressures in the energy drink sector and macroeconomic sensitivity could challenge margins. Institutional sentiment is cautiously optimistic, with upside potential to the consensus target representing 11% gain from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →